Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases

October 7, 2026 updated by: Shirley Vichy Wang, Brigham and Women's Hospital

Emulation of the MAVERICC (NCT01374425) Trial Using Specialty Oncology Electronic Health Records Databases

This trial emulation study aims to emulate the MAVERICC trial (NCT01374425) using real-world specialty oncology electronic health record data and to investigate the concordance between the trial's original and emulated treatment effect estimates on overall survival (OS). MAVERICC was a Phase II, open-label, randomized study assessing the efficacy and safety of modified leucovorin/5-fluorouracil/ oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Randomized controlled trials (RCTs) are generally regarded as the gold-standard of evidence for establishing efficacy of medical products. However, real-world data (RWD) are increasingly used to complement evidence from RCTs. Yet, to have confidence in the accuracy of non-interventional studies medical products and their outcomes in oncology, investigators need to know what questions can be validly answered, with which non-interventional study designs, and which analysis methods are appropriate, given the data that is available. Building on a process from the RCT DUPLICATE initiative, EmulatioN of Comparative Oncology trials with Real-world Evidence (ENCORE) is the trial emulation discussed in this protocol, which is part of the expansion project specific to oncology and aims to emulate 12 randomized oncology RCTs using multiple EHR data sources.

The purpose of this protocol is to describe the emulation of the MAVERICC trial. MAVERICC was a Phase II, open-label, randomized study assessing the efficacy and safety of modified leucovorin/5-fluorouracil/ oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).

Study Type

Observational

Enrollment (Actual)

9978

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Somerville, Massachusetts, United States, 02145
        • Brigham and Women's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults with previously untreated metastatic colorectal cancer who initiated FOLFIRI plus bevacizumab or mFOLFOX6 plus bevacizumab as first-line treatment.

Description

Inclusion Criteria:

  • Age 18 years or older at first-line study regimen initiation.
  • Metastatic colorectal cancer documented in a specialty oncology electronic health record.
  • Initiation of FOLFIRI plus bevacizumab or mFOLFOX6 plus bevacizumab as first-line systemic treatment for metastatic disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 when ascertainable in the database.

Exclusion Criteria:

  • Evidence of brain metastases at or before study regimen initiation.
  • Prior systemic treatment for metastatic colorectal cancer.
  • Adjuvant chemotherapy within 12 months before study regimen initiation.
  • Another primary malignancy within five years before study regimen initiation, except cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ.
  • Use of an investigational agent within 28 days before study regimen initiation.
  • Other anticancer treatment during the treatment assessment window, where ascertainable in the database.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Initiation of FOLFIRI plus bevacizumab

Observed initiation of first-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.

Other Names:
  • FOLFIRI-BV
Initiation of mFOLFOX6 plus bevacizumab

Observed initiation of first-line mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.

Other Names:
  • mFOLFOX6-BV

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to all-cause mortality (overall survival)
Time Frame: From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)

Hazard ratio (95% CI)

From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Shirley V Wang, PhD, ScM, Brigham and Women's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 20, 2026

Primary Completion (Estimated)

October 20, 2026

Study Completion (Estimated)

October 20, 2026

Study Registration Dates

First Submitted

September 29, 2026

First Submitted That Met QC Criteria

October 5, 2026

First Posted (Actual)

October 6, 2026

Study Record Updates

Last Update Posted (Actual)

October 13, 2026

Last Update Submitted That Met QC Criteria

October 7, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2022P002556-ENC-MAVERICC
  • 75F40122C00181 (Other Grant/Funding Number: Food and Drug Administration)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.